Sign in →

Test Code LABMDDNAONCOCYT DNA OncoPlus FFPE/Cytology

Specimen and Container/Tube

Specimen Type: Tumor Tissue
Preferred Specimen: FFPE Slides or Cytology Smear
Other Acceptable Specimens: not applicable

Appropriate specimens should contain >20% tumor cells and enough total cells to produce adequate DNA yield (typically >50,000 total cells (FFPE) or >2000 total cells (cytology smear)). Specimens with less than 20% tumor cells may be tested at the discretion of the attending molecular pathologist.

Volume

Minimum Volume: 10 slides (FFPE), 1 slide (Cytology Smear)

Unstained slides containing FFPE tissue are acceptable. At least 10 microtome sections of 5 micron thickness should be submitted for testing. One adequate cytology smear should be submitted for testing.

Specimen Stability

N/A

Collection Instructions

Collect specimen per standard laboratory collection procedures.

Specimen Handling and Transport Instructions

UCM Onsite Instructions: Collect specimen per standard collection procedured and send to the laboratory immediately.

Turnaround Time

Turnaround times are relative to the time the specimen is received in the testing laboratory section.

STAT Turnaround Time: n/a
Routine Turnaround Time: ≤14 days

Testing Schedule: M-F 7:00am-5:00pm

Clinical Indications

The OncoPlus panel is a universal cancer mutation, next generation sequencing (NGS) assay that has the capability to cover more than 1,005 cancer-related genes, of which 168 genes are clinically reported, for personalized assessments of both solid tumors and hematological malignancies. Additional reportable features include tumor mutational burden (TMB), microsatellite stability status, and copy number alterations.

Test Components

Genes analyzed for mutations and insertions/deletions (168): ABL1, AKT1, ALK, APC, ARID1A, ARID2, ASXL1, ATM, ATR, ATRX, AXL, B2M, BAP1, BCOR, BCORL1, BIRC3, BLM, BRAF, BRCA1, BRCA2, BTK, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CCNE1, CD274, CDH1, CDK4, CDK6, CDK12, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DICER1, DNMT3A, EGFR, ELOC, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA1, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3-3A, H3C2, H3C3, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDM6A, KDR, KEAP1, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MDM2, MET, MEN1, MLH1, MLH3, MPL, MRE11, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PAX5, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD50, RAD51, RB1, RET, ROS1, RUNX1, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SRSF2, STAG2, STAT3, STAT5B, STK11, TERT, TET2, TP53, TRAF7, TSC1, TSC2, U2AF1, VHL, WT1, ZRSR2

Genes analyzed for copy number variations (145 gene subset): ABL1, AKT1, ALK, APC, ARID1A, ARID2, ASXL1, ATM, ATR, AXL, B2M, BAP1, BIRC3, BLM, BRAF, BRCA1, BRCA2, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CCNE1, CD274, CDH1, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX41, DICER1, DNMT3A, EGFR, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3-3A, H3C2, H3C3, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDR, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MDM2, MET, MLH1, MLH3, MPL, MRE11, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, PALB2, PBRM1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51, RB1, RET, RUNX1, SDHB, SDHC, SDHD, SETBP1, SF3B1, SMAD4, SMARCB1, SMC3, SMO, SRSF2, STAT3, STAT5B, STK11, TERT, TET2, TP53, TSC1, TSC2, U2AF1, VHL, WT1

Genes analyzed for fusions/translocations (3): ALK, RET, and ROS1

CPT Codes

81450

Methodology

The test procedure involves DNA extraction and quantity/quality assessment, fragmentation and library preparation, followed by pooled capture targeting the desired genomic loci. Next generation sequencing (NGS) is performed on the Illumina platform and downstream analysis for quality control and detection of mutations is performed via custom-design bioinformatics pipelines on a HIPAA-compliant high performance computing system within the Center for Research Informatics (CRI).

Synonyms/Key Search Words

CNV, copy number, cancer, mutation, panel, NGS, NextGen, Sequencing, Gene

Additional Information

Appropriate specimens should contain >20% tumor cells and enough total cells to produce adequate DNA yield (typically >50,000 total cells). Specimens with less than 20% tumor cells may be tested at the discretion of the attending molecular pathologist.